Prostacyclin for HIV-Associated Pulmonary Hypertension
Authors: Hans Stricker
Journal: Annals of Internal Medicine (1997)

Letters1 December 1997Prostacyclin for HIV-Associated Pulmonary HypertensionHans Stricker, MD, Guido Domenighetti, MD, and Giorgio Mombelli, MDHans Stricker, MDRegional Hospital; CH-6600 Locarno, SwitzerlandSearch for more papers by this author, Guido Domenighetti, MDRegional Hospital; CH-6600 Locarno, SwitzerlandSearch for more papers by this author, and Giorgio Mombelli, MDRegional Hospital; CH-6600 Locarno, SwitzerlandSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-11-199712010-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Primary pulmonary hypertension is a progressive, therapy-resistant illness associated with a median survival of 2.8 years; the mortality rate correlates with measures of right ventricular function [1]. A promising new therapeutic strategy includes long-term intravenous [2] or aerosolized [3] administration of prostacyclin.Recent reports suggest an increased incidence of pulmonary hypertension, probably unrelated to the degree of immunodeficiency, in HIV-infected persons [4]. We describe two HIV-infected patients with pulmonary hypertension who were treated for 7 months with aerosolized prostacyclin. Both 33-year-old, formerly drug-addicted men were given a diagnosis of pulmonary hypertension after the American College of Chest ...References1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115:343-9. Google Scholar2. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch BD, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334:296-301. Google Scholar3. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimmiger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996; 124:820-4. Google Scholar4. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest. 1991; 100:1268-71. Google Scholar5. Rubin LJ. Primary pulmonary hypertension. Chest. 1993; 104:236-50. Google Scholar Author, Article, and Disclosure InformationAffiliations: Regional Hospital; CH-6600 Locarno, Switzerland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByAdvances in the diagnosis and treatment of HIV-associated pulmonary arterial hypertensionPulmonary Hypertension in HIVPulmonary Arterial Hypertension in Human Immunodeficiency Virus InfectionHIV-related pulmonary arterial hypertension: clinical presentation and managementHipertensión arterial pulmonar en el año 2004Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral TherapyCurrent Management of Pulmonary HypertensionCLINICAL CLASSIFICATION OF PULMONARY HYPERTERNSIONEpoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary HypertensionHipertensión pulmonar en los pacientes con infección por el virus de la inmunodeficiencia humana. Estudio de 14 casosPulmonary Hypertension Associated with HIV, Liver Disease, Sarcoidosis, and Sickle Cell Disease 1 December 1997Volume 127, Issue 11Page: 1043KeywordsDrugsDyspneaHeartInhalationProstacyclinPulmonary arteriesPulmonary hypertensionSystolic pressureThoraxWalking Issue Published: 1 December 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...